KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for ClearPoint Neuro (CLPT) over the last 6 years, with Q3 2025 value amounting to $617218.0.

  • ClearPoint Neuro's Gains from Sales and Divestitures changed N/A to $617218.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $617218.0, marking a year-over-year change of. This contributed to the annual value of $270673.0 for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, ClearPoint Neuro's Gains from Sales and Divestitures is $617218.0.
  • In the past 5 years, ClearPoint Neuro's Gains from Sales and Divestitures registered a high of $1.6 million during Q2 2021, and its lowest value of $270673.0 during Q4 2024.
  • Over the past 3 years, ClearPoint Neuro's median Gains from Sales and Divestitures value was $615315.0 (recorded in 2025), while the average stood at $783584.3.
  • Data for ClearPoint Neuro's Gains from Sales and Divestitures shows a peak YoY increase of 27196.08% (in 2021) and a maximum YoY decrease of 16905.84% (in 2021) over the last 5 years.
  • ClearPoint Neuro's Gains from Sales and Divestitures (Quarter) stood at $1.6 million in 2021, then plummeted by 83.02% to $270673.0 in 2024, then soared by 128.03% to $617218.0 in 2025.
  • Its last three reported values are $617218.0 in Q3 2025, $613412.0 for Q2 2025, and $455585.0 during Q1 2025.